You are here

Article Text

Article menu

Download PDFPDF

Arrhythmias and sudden death
Original research article
Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women
  1. Haruki Sekiguchi1,2,3,4,
  2. Ken Shimamoto1,3,5,
  3. Mayu Takano1,3,
  4. Makiko Kimura1,3,
  5. Yufuko Takahashi1,3,
  6. Fujio Tatsumi1,3,
  7. Eri Watanabe1,3,
  8. Kentaro Jujo3,
  9. Naoko Ishizuka3,4,
  10. Masatoshi Kawana1,3,5,
  11. Nobuhisa Hagiwara3
  1. 1 Cardiology, Aoyama Hospital, Tokyo Women’s Medical University, Tokyo, Japan
  2. 2 Cardiology, National Hospital Organization Yokohama Medical Center, Kanagawa, Japan
  3. 3 Cardiology, Tokyo Women’s Medical University, Tokyo, Japan
  4. 4 Cardiology, Institute of Geriatrics Tokyo Women’s Medical University, Tokyo, Japan
  5. 5 General Medicine, Tokyo Women's Medical University, Tokyo, Japan
  1. Correspondence to Dr Haruki Sekiguchi, Department of Cardiology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjyuku Ward, Tokyo 162-8666, Japan; gucci_0418{at}yahoo.co.jp

Abstract

Objective Plasma cancer antigen (CA)-125 is a tumour marker recently shown to be associated with systolic heart failure and new-onset atrial fibrillation (AF) after myocardial infarction. However, no reports have described the relationship between CA-125 and new-onset AF in healthy postmenopausal women. The aim of the present study was to evaluate the relationship between CA-125 and new-onset AF in postmenopausal women.

Methods Between 2005 and 2015, 2086 women, including 1012 postmenopausal women, visited our hospital for annual health check-ups. We excluded patients with systolic dysfunction, chronic inflammatory disease, chronic obstructive pulmonary disease, histories of AF or neoplastic diseases. A total of 746 postmenopausal women underwent thorough physical examinations, including those for biomarkers such as brain natriuretic peptide, high-sensitivity C-reactive protein (hs-CRP) and CA-125.

Results During the 10-year observation period, AF was documented in 31 participants (4.2%). The mean age of participants developing AF (75±6 years) was higher than that of those without AF (68±8 years). Participants developing AF showed significantly higher CA-125 (11.4±6.3 U/mL) and hs-CRP (0.10±0.11 mg/dL) levels than did those without AF (7.7±3.2 U/mL, p<0.01; 0.07±0.08 mg/dL, p<0.05). Cox regression analyses revealed ageing (HR 1.3; 95% CI 1.08 to 1.57; p<0.01) and plasma CA-125 levels (HR 1.29; 95% CI 1.10 to 1.51; p=0.02) as independent predictors of AF.

Conclusions High CA-125 levels might be associated with new-onset AF in healthy postmenopausal women.

  • Atrial Fibrillation
  • Inflammatory markers
  • Epidemiology

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/heartjnl-2016-310272

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors HS led the study as the principal investigator, initiated the project, wrote the statistical analysis plan and drafted and revised the paper. KS wrote the statistical analysis plan, and cleaned and analysed the data. MT, YT, FT and EW collected the data. KJ designed the data collection tools and analysed the data. MK analysed the data and drafted and revised the paper. NH critically reviewed the draft of the manuscript. All authors approved the final version of the manuscript.

    • Competing interests None declared.

    • Ethics approval The Human Research Protection Office of Tokyo Women’s Medical University approved this protocol (#2507).

    • Provenance and peer review Not commissioned; externally peer reviewed.